The emergence of antibiotic resistance has severely reduced the effectiveness of all antibiotics clinically used today. At the same time very few fundamentally new antibiotics have been developed in the past 20 years. Thus, we are rapidly running out of treatment options for CPE infections. Development of new lead compounds is a difficult, high-risk problem that requires a multidisciplinary approach.
CARe aim to, in collaboration with health care and industry, identify new treatment options and to develop new antibiotic substances.